indinavir + ritonavir + didanosine + stavudine

**indinavir + ritonavir + didanosine + stavudine** is a four-agent antiretroviral combination used in the treatment of HIV infection. This regimen includes: - **Indinavir:** a protease inhibitor, prevents HIV protease from processing viral proteins, thus inhibiting viral maturation. - **Ritonavir:** a protease inhibitor, commonly used at low dose to boost blood levels of other protease inhibitors like indinavir by inhibiting cytochrome P450 3A4, enhancing antiviral efficacy. - **Didanosine:** a nucleoside reverse transcriptase inhibitor (NRTI), incorporated into viral DNA resulting in chain termination and inhibition of HIV replication. - **Stavudine:** a nucleoside reverse transcriptase inhibitor (NRTI), also causes chain termination of viral DNA synthesis. Combination therapy with these agents has demonstrated potent suppression of HIV-1 RNA and increases in CD4+ lymphocytes, particularly in children and adults with HIV infection[1][2][4]. This regimen is employed mainly where multiple drug therapy is needed to prevent resistance and achieve maximal viral suppression.

Brand names

Crixivan (indinavir)Norvir (ritonavir)Videx (didanosine)Zerit (stavudine)

Other names

indinavir sulfateritonavirddI (didanosine)d4T (stavudine)